Table 2.

Counts and Annualized Rates for Outcomes in the Women’s Health Initiative Estrogen-Alone Trial Among Postmenopausal Women Enrolled in 1993–1998 at Ages 50–79 Years Across 40 Clinical Centers, United States, With Cumulative Follow-up Through 2016

	Subgroup Aged 50–59 Years (n = 3,313)				Trial of CEE Alone (n = 10,739)
Outcome	CEE (n = 1,639)		Placebo (n = 1,674)		CEE (n = 5,310)		Placebo (n = 5,429)
	No.	%	No.	%	No.	%	No.	%
Intervention Phase
Primary outcomes
Coronary heart disease	21	0.17	35	0.28	205	0.55	222	0.58
Invasive breast cancer	29	0.24	36	0.29	103	0.28	135	0.35
Other monitored outcomes
Stroke	19	0.16	21	0.17	174	0.47	130	0.34
Pulmonary embolism	12	0.099	8	0.064	52	0.14	39	0.10
Colorectal cancer	9	0.074	13	0.10	65	0.17	58	0.15
Hip fracture	5	0.041	1	0.008	48	0.13	74	0.19
All-cause mortalitya	35	0.29	50	0.40	301	0.80	299	0.77
Global indices
Univariate	117	0.98	142	1.17	756	2.09	754	2.04
Multivariate	130	1.07	164	1.31	948	2.51	957	2.47
Cumulative Follow-up
Primary outcomes
Coronary heart disease	71	0.27	91	0.35	521	0.69	550	0.71
Invasive breast cancer	73	0.28	92	0.36	231	0.30	291	0.38
Other monitored outcomes
Stroke	49	0.19	58	0.22	399	0.53	392	0.50
Pulmonary embolism	35	0.13	34	0.13	153	0.20	150	0.19
Colorectal cancer	18	0.069	26	0.10	119	0.15	118	0.15
Hip fracture	19	0.073	20	0.077	208	0.27	229	0.29
All-cause mortalitya	156	0.59	184	0.70	1,258	1.62	1,277	1.61
Global indices
Univariate	334	1.35	393	1.61	1997	2.84	2078	2.91
Multivariate	421	1.61	505	1.93	2,889	3.72	3,007	3.79

Abbreviation: CEE, conjugated equine estrogens

^a For consistency with other monitored outcomes included in the global index, extended follow-up includes only participants who provided consent for long-term follow-up.